Search
Valbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalValbenazine is a modified metabolite of tetrabenazine, and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesTelotristat ethyl
go.drugbank.com/drugs/DB12095ApprovedTelotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the n...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigationalGepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. ciprofloxacin - while being structurally and p...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGilteritinib
go.drugbank.com/drugs/DB12141ApprovedInvestigationalGilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesPropiverine
go.drugbank.com/drugs/DB12278ApprovedPropiverine is a widely used antimuscarinic drug with a mixed mode of action in the treatment of symptoms associated with overactive bladder (OAB) . Overactive bladder (OAB) is a chronic condition of the lower urinary tract characterized...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEravacycline
go.drugbank.com/drugs/DB12329ApprovedInvestigationalEravacycline, known as Xerava by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacte...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCopanlisib
go.drugbank.com/drugs/DB12483ApprovedInvestigationalCopanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell surviva...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigationalOlanzapine is an effective atypical antipsychotic that, like other antipsychotics, is associated with weight gain, metabolic dysfunction, and increased risk of type II diabetes. Samidorphan is a novel opioid antagonist structurally relat...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesBenserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalThis can result in a number of side effects like nausea, vomiting, or even cardiac arrhythmias that may diminish patient adherence [F2, L2553].
Mixtures: LEVODOPA P BENS AL 100/25, LEVODOPA P BENS AL 100/25Quizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalQuizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated with other targets in mind. A...
Categories: P-glycoprotein inhibitors, P-glycoprotein substrates